Stage III Melanoma: Clinical Trials

20 trials for Stage III Melanoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 4 terminated, 2 withdrawn, 1 unknown. 20 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 220Completed 13, Terminated 4, Withdrawn 2, Unknown 1
Phase 14Completed 3, Terminated 1

Follow Stage III Melanoma: new trials by email Literature Review of Stage III Melanoma trials Research Report on Stage III Melanoma

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sargramostim (GM-CSF) + PD-1
Sargramostim (GM-CSF), Pembrolizumab (anti-PD-1) - Unresectable Melanoma, Metastatic Melanoma
Phase 2WithdrawnDana-Farber Cancer Institute2021-04-162023-05-22
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab - Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
Phase 2CompletedEmory University152019-06-052026-10-02
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
Trametinib, Dabrafenib - Stage IV Melanoma, Stage III Melanoma
Phase 2CompletedUniversitair Ziekenhuis Brussel452019-01-282023-09-26
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Pembrolizumab with All-Trans Retinoic Acid - Stage IV Melanoma, Stage III Melanoma
Phase 1 / Phase 2CompletedUniversity of Colorado, Denver262017-10-312024-10-01
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Pembrolizumab - Unresectable Malignant Neoplasm, Melanoma
Phase 2CompletedSt. Louis University102015-01-012019-06-20
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Indoximod, Ipilimumab, Nivolumab - Metastatic Melanoma, Stage III Melanoma
Phase 1 / Phase 2CompletedNewLink Genetics Corporation1312014-07-012026-05-29
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
BRAF inhibitor dabrafenib and MEK inhibitor trametinib - Stage III Melanoma, Stage IV Melanoma
Phase 2CompletedUNC Lineberger Comprehensive Cancer Center172013-04-042020-11-23
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
Ofatumumab, Ofatumumab plus Dacarbazine - Stage III Melanoma, Stage IV Melanoma
Phase 2CompletedMedical University of Vienna102011-06-012015-10-06
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
MKC1106-MT - Stage III Melanoma, Stage IV Melanoma
Phase 2TerminatedMannkind Corporation52010-10-012012-05-15
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Pazopanib and Paclitaxel - Stage III Melanoma, Stage IV Melanoma
Phase 2CompletedUniversity of California, Irvine602010-08-012019-08-07
Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Nilotinib - Malignant Skin Melanoma T0, Stage III Melanoma
Phase 2UnknownAssistance Publique - Hôpitaux de Paris252010-07-012011-02-08
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox - Recurrent Melanoma, Stage III Melanoma
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center32009-07-012022-11-15
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ziv-aflibercept, pharmacological study - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
Phase 2CompletedNational Cancer Institute (NCI)412007-06-012018-05-24
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
sorafenib tosylate, temsirolimus - Melanoma, Recurrent Melanoma
Phase 2WithdrawnNational Cancer Institute (NCI)2006-04-012015-04-15
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
sorafenib tosylate, laboratory biomarker analysis - Stage III Melanoma, Stage IV Melanoma
Phase 2CompletedNational Cancer Institute (NCI)742005-06-012013-01-15
Tanespimycin in Treating Patients With Stage III-IV Melanoma
tanespimycin, laboratory biomarker analysis - Recurrent Melanoma, Stage III Melanoma
Phase 2TerminatedNational Cancer Institute (NCI)502004-06-012013-04-10
Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
cilengitide, pharmacological study, laboratory biomarker analysis - Stage III Melanoma, Stage IV Melanoma
Phase 2TerminatedNational Cancer Institute (NCI)562004-03-012013-06-05
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
imatinib mesylate, bevacizumab, pharmacological study - Recurrent Melanoma, Stage III Melanoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)402003-10-012018-06-20
Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
allovectin-7 - Stage IV Melanoma, Stage III Melanoma
Phase 2CompletedVical781998-08-012011-07-07
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
dendritic cell-gp100-MART-1 antigen vaccine, sargramostim - Stage IV Melanoma, Stage III Melanoma
Phase 2CompletedNational Cancer Institute (NCI)2024-03-04

Narrower conditions

Melanoma (20)  ·  Neoplasms (2)  ·  Skin Neoplasms (2)  ·  Recurrence (1)  ·  Uveal Melanoma (1)

Broader conditions

Neoplasms by Histologic Type (20)  ·  Neoplasms by Site (20)  ·  Neoplasms, Germ Cell and Embryonal (20)  ·  Neoplasms, Nerve Tissue (20)  ·  Neuroectodermal Tumors (20)  ·  Neuroendocrine Tumors (20)  ·  Nevi and Melanomas (20)  ·  Skin Diseases (20)  ·  Skin and Connective Tissue Diseases (20)  ·  Neoplasms (18)  ·  Skin Neoplasms (18)  ·  Disease Attributes (1)  ·  Eye Diseases (1)  ·  Eye Neoplasms (1)  ·  Pathologic Processes (1)

Interventions

pembrolizumab (4)  ·  Ipilimumab (2)  ·  Nivolumab (2)  ·  Sorafenib (2)  ·  sargramostim (2)  ·  1-methyltryptophan (1)  ·  Allovectin-7 (1)  ·  Bevacizumab (1)  ·  Biopsy (1)  ·  Cilengitide (1)  ·  Dacarbazine (1)  ·  Granulocyte-Macrophage Colony-Stimulating Factor (1)  ·  Imatinib Mesylate (1)  ·  Immunohistochemistry (1)  ·  Interleukin-2 (1)

Sponsors

National Cancer Institute (NCI) (7)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Dana-Farber Cancer Institute (1)  ·  Emory University (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Mannkind Corporation (1)  ·  Medical University of Vienna (1)  ·  NewLink Genetics Corporation (1)  ·  St. Louis University (1)  ·  UNC Lineberger Comprehensive Cancer Center (1)  ·  Universitair Ziekenhuis Brussel (1)  ·  University of California, Irvine (1)  ·  University of Colorado, Denver (1)  ·  Vical (1)

Countries

United States (14)  ·  Austria (1)  ·  Belgium (1)  ·  France (1)

Top investigators

Kevin Kim (2)  ·  Ahmad Tarhini (1)  ·  Anna Pavlick (1)  ·  Bart Neyns, MD, PhD (1)  ·  Carrie Lee, MD (1)  ·  Celeste Lebbe, MD, PhD (1)  ·  Elizabeth Buchbinder, MD (1)  ·  Jennifer Fernandez (1)  ·  John Fruehauf, MD, PhD (1)  ·  John M Richart, MD (1)  ·  Kavita Dhodapkar, MD (1)  ·  Keith Flaherty (1)  ·  Klemens Rappersberger, Prof. Dr. (1)  ·  Martin McCarter, MD (1)

Results publications

PMID 21206909, PMID 29943192, PMID 39374099, PMID 42640721

NIH funding

N01CM62202 (2), K12CA076930 (1), N01CM62204 (1), N01CM62206 (1), N01CM62209 (1), P30CA033572 (1), R21CA137647 (1)